INTRODUCTION
Study of the genetics of atopy has proved controversial, and debate has been fuelled by the complexity of the clinical and immunological phenotype and by the undoubtedly heterogeneous genetics.
There is now ample evidence that one significant locus is located on chromosome 11q13 [l-51. The beta-unit of the high-affinity IgE receptor is currently the principal candidate gene at this location, and three variants of the gene, two coding (Ile-181 +Leu, Gly-237+Glu) and one intronic, have been identified and shown to be strongly associated with the atopy phenotype in population surveys [6-91. There are no published data on the functional consequences of any of these variants. The investigation of such consequences may prove to be difficult because of the complexity of the atopy phenotype and because FceRI is expressed on a range of cells where is may have different functions, the mast cell, the basophil, the monocyte, the eosinophil and the antigen-presenting Langerhan's cell [lo-141.
FceRI is a tetrameric complex composed of an a-chain, which binds IgE, a )-chain and a dimer of y-chains, which are required for insertion of the a-chain into the membrane and for signal transduction across the membrane into the cytoplasm [lo] . Recent studies on the characteristics of the P-chain in FceRI-dependent signalling demonstrate that the y dimer functions as an autonomous activation module, whilst the P-chain functions as an amplifier that provides a gain of 5-to 7-fold in cell-activation signals [15] . The P-subunit of F a R I contains four trans-membrane segments [ 161; surface expression of mutated subunits of FceRI showed that minor changes within the trans-membrane segments can cause significant changes in the receptor's expression and function, as measured by rosetting assays [17] . Thus Ile-1814Leu lies at a strategic position for receptor display, and might influence receptor function.
Here we report a preliminary, qualitative study of histamine release by skin mast cells in vivo and basophils in vitro in response to allergen challenge in atopic individuals with Ile-181 +Leu compared with the response in similarly atopic, unrelated individuals without Ile-181 +Leu.
SUBJECTS
Sixty British nuclear families, recruited through an atopic asthmatic proband, have previously been phenotyped for atopy and genotyped for Ile-l81+Leu [9] . Ile-l81+Leu was identified by DNA allelespecific PCR and confirmed by genomic DNA sequencing, and was found in ten families; all the children inheriting Ile-l81+Leu by maternal descent were atopic [9] .
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The informed consent of all participants and ethics committee approval for the study were obtained.
Nineteen individuals form the basis of the current study: nine Ile-l81+Leu subjects from seven of the ten Ile-l81+Leu+ families (shown in family trees, Fig. 1 ) and ten Ile-181 subjects, one each from ten of the remaining 50 families without Ile-181 +Leu.
There were more female subjects in the Ile-181-+Leu group (7 females, 2 males; total 9) because of subject availability and, consequently, more female subjects were selected for the Ile-181 group (7 females, 3 males; total 10). The mean age of the Ile-181 group (35 5-1 year, range 19-47 years)
was not significantly different from that of the Ile-181 group (365-1 year, range 20-46 years). Younger children were excluded from this study because of the need for multiple skin prick testing (SPT) and the relatively large volume of blood required for the basophil experiments.
Anti-histamines were withheld for 2 weeks before the subjects entered the study, but patients continued using topical bronchodilators or topical corti- costeroids for control of their atopic asthma if necessary. Studies on all subjects were conducted between January and April (out of the pollen season).
METHODS

Allergen SPT for mast cell sensitivity
The classic demonstration of an allergic response involving skin mast cells is the wheal and flare reaction seen in SPT of atopic individuals. A drop of allergen in diluent is placed on the forearm and lightly pricked into the skin with a lancet; in the sensitized subject, IgE bound to mast cells becomes cross-linked and the skin mast cells degranulate with the rapid release of inflammatory mediators and the wheal and flare responses. We conducted doseresponse skin testing to allergens. A series of 10-fold dilutions of the allergens, from 10-1 to were made freshly from stocks [house dust mite (HDM) (30 000 U/ml) and Timothy grass pollen (GP) (40 000 U/ml)] in sterile albumidsaline diluent (Dome/Hollister-Stier, Division of Miles Inc., Spokane, WA, U.S.A.). Wheal responses to each dilution were measured in duplicate and plotted to construct a dose-response curve.
Histamine release from peripheral blood basophils
Histamine is a potent mediator stored in large amounts in the granules of basophils and mast cells. The mononuclear cell fraction with approximately 2% basophils was isolated from peripheral blood by dextran sedimentation. Since only the basophil leucocytes contain histamine, which is hence a -- specific basophil-activation marker, such a fraction can be used for studying basophil histamine release without further proliferation.
The procedure utilized in the histamine-release assay was modified from James et al. [18] . Venous blood (40 ml) was anticoagulated with 4 ml (1 : 10 volume) of 0.1 mol/l EDTA (pH 7.4) and was carefully mixed with 10 ml (1 : 4 volume) of 6% Dextran T70 (pH 7.4; Pharmacia). Erythrocytes were allowed to sediment for 90min at room temperature. The leucocyte-containing plasma was collected and centrifuged at 300g for 10 min.
The cell pellet was washed three times in ice-cold HA buffer [20 mmol/l Hepes/l25 mmol/l NaC1/ 5 mmol/l glucoseR mmol/l KC1/0.03% (w/v) human serum albumin], resuspended in HACM buffer (HA buffed1 mmol/l MgCld1 mmol/l CaClz), and kept on ice. The basophil number was counted by impulse sorting using a haematology analyser. The final basophil concentration was adjusted to (1.5-2) x 105/ml in HACM buffer. A 10-fold series of dilutions for each stimulus were made freshly from the stocks in HACM buffer just before cell challenge. HDM and GP were as described above and rabbit polyclonal anti-human IgE (2 mglml) was obtained from Dako, Carpenteria, CA, U.S.A. All other reagents were obtained from Sigma.
Cell suspension (100 pl volumes) containing (1.5-2) x lo4 basophils and 100 p1 of each dilution were pre-warmed separately at 37°C for 5 min. The dilutions were then added into the cell suspensions and gently mixed. The samples were incubated with gentle shaking for 45 min at 37°C. Spontaneous histamine release was measured by incubating 100 pl of the cell suspension and 1OOpl of HACM buffer without any of the stimuli. Mean total histamine content was determined by boiling 100 pl of the cell suspension and 100 pl of HACM buffer for 10 min. After incubation, all of the cell suspensions were spun at 900g for 10 min at 4°C. The supernatants were collected and stored at -70°C until histamine determination was performed. The concentration of histamine in the supernatant was measured using a competitive immunoassay with histamine acetylcholinesterase (histamine enzyme immunoassay kit, Immunotech International). The intra-and interassay variation of the kit was less than 5%. The results were expressed as percentages of the total cellular histamine and are corrected for the spontaneous release of the histamine.
Statistics
groups were tested using the Mann-Witney test.
Differences between the Ile-181 +Leu and Ile-181
RESULTS
Skin mast cell sensitivity
The data for SPT reactions to HDM and GP in subjects with and without the Leu-181 variant for FceRI-P are shown in Tables 1 and 2 and Fig. 2. As expected, the individuals tested showed dosedependent skin reactions to HDM and GP allergens.
In skin reactions to HDM ( (Fig. 2) . However, neither result was statistically significant, perhaps reflecting the small sample size utilized in this study.
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In skin reactions to GP (Table 2 and Fig. 2) , the Ile-181 group were somewhat more sensitive to the high concentration of GP allergen. There were some more general positive responses at GP concentrations of and low4 dilutions in comparison with the Ile-l81+Leu group, but again, this did not reach statistical significance. There was no noticeable difference in SPT reactions to GP between Leu-181 and Ile-181 subjects with similar allergenspecific serum IgE levels.
Subjects who had high specific IgE levels (RAST class 3 or above) had more sensitive skin prick test reactions than the subjects who had low specific IgE levels (below RAST class 2), which indicates a correlation between the skin mast cell sensitivity and serum-specific IgE level. However, there is a Grass pollen allergen ( log dilution ) 
10-100-fold dose variation in skin mast cell sensitivity to the allergens tested in subjects with the same serum-specific IgE levels.
Basophil histamine release
In the subjects studied, the percentage of basophils varied from 0.1 to 2% and was not different from those reported previously [19] .
The release of the preformed mediator histamine was compared for Ile-l81+Leu and Ile-181 subjects. There was no significant difference in spontaneous histamine release [Ile-181 +Leu, 2.3 f 0.7 (range 0.5-5.2%); Ile-181, 3 f0.9 (range 0-4.8%)] in the two study groups.
Histamine release induced by anti-IgE is shown in Table 3 and Fig. 3 . There was no noticeable difference in the concentration of anti-IgE required for anti-histamine release from basophils in both groups below a dilution (0.02 pg/ml) of anti-IgE. The maximum histamine release (MHR) was observed consistently at a dosage between to dilutions (0.02 pg/ml); but at the same concentration of anti-IgE, histamine release varied widely, ranging from 3 to 43% (O.O2,ug/ml), from 27 to 70% (0.2 pg/ml) and from 27 to 93% (2 pg/ml).
Histamine releases from basophils induced by HDM and GP allergens are shown in Tables 4 and 5 and Fig. 3 . More variation in basophil histamine release was seen with allergen stimuli compared with anti-IgE stimulation. MHR was related to the concentration of specific allergen used, but varied widely at 10-1000-fold variations in allergen concentration.
Using HDM as the stimulus, two out of six subjects (HH2, HH3) with the Ile-lSl-Leu variant showed significant histamine release ( > 10% of total histamine content) from basophils at dilution, which is a 10-fold lower dose of HDM compared with that required to initiate histamine release from subjects with Ile-181, who had similar allergenspecific serum IgE levels ( Table 4) .
When histamine release was induced by GP ( Table 5 , Fig. 3) , there was no significant difference between subjects with and without Leu-181 who had allergen-specific serum IgE levels.
Two Ile-l81+Leu subjects (HH1, HP1) with very low specific IgE levels against specific allergens (skin tests giving 2 and 4 mm wheals respectively, but no detectable specific IgE in serum), showed histamine release in response to lop2 dilution of HDM and dilution of GP (Tables 4 and 5) . Both subjects showed >50% histamine release at high concentrations of allergen, compared with <30% histamine release in the Ile-181 subject (HM1).
DISCUSSION
Our studies on skin mast cell reactions and basophi1 histamine release induced by HDM antigen in subjects with the Ile-181 +Leu variant of FccRI-P, demonstrate that some of these individuals show enhanced sensitivities to the allergen. The skin mast cells and basophils of these individuals reacted to a 10-fold lower concentration of HDM allergen, and released more of their total histamine at intermediate allergen doses, compared with atopic subjects with normal FceRI-P. In SPT reactions to GP, the Leu-181 group were somewhat more sensitive to the high concentration of GP allergen. These findings are not explicable by any agehex effect, nor is the trend shown in one particular family. However, these differences do not reach statistical significance. The spontaneous release of histamine from basophils was not statistically different between the two study groups; this suggests that the Ile-181 +Leu variant does not lead to a marked change in the constitutive activity of FceRI, although any subtle effect is beyond the sensitivity of the present assay. It has been reported previously that there is a good correlation between the serum and cell-bound IgE concentrations (r = 0.89, P < O.OOl), but that the relationship between cell-bound IgE and the antiIgE concentration required for histamine release is poor. Basophils from non-atopic donors were as sensitive as basophils from allergic donors, and cells from donors having approximately the same cellbound IgE varied widely in their sensitivity to antiIgE. Moreover, basophils display a wide variation in the extent of histamine release when challenged with an optimal concentration of polyclonal anti-IgE [20, 211. We have found similar effects in the present study. When a wide range of specific allergen concentrations, HDM and GP from to 10-lo dilutions, were tested, there was no correlation between MHR, specific IgE levels and the concentration of specific allergen required for histamine release. Individuals with or without the Leu-181 variant varied widely in their MHR and the concen- tration of allergens required for histamine release. The wide variation of dose-responses to specific allergens in subjects with the same magnitude of serum-specific IgE levels suggests an intrinsic property of mast cells and basophils which determines sensitivity to specific allergens beyond the serum or cell surface allergen-specific IgE levels [20, 221. This intrinsic variability makes data interpretation difficult, especially in a study such as the present one, where only small numbers of subjects were available. The results of this study are inconclusive and do not show a decisive relationship between Ile181+Leu and enhanced basophil and mast cell release of histamine. More refined functional experiments are required, taking account of the widespread cellular expression of FceRI, to determine whether the Ile-181 +Leu of FceRI-P has functional effects, or whether this genetic variant is a marker for another functional variant within the controlling elements of FceRI, or indeed within another, as yet unidentified genetic locus contiguous with FceRI-P on chromosome 11.
